Press Releases | Regeneron Pharmaceuticals Inc.
WEBSep 20, 2024 — Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer. Sep 9. Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO. Aug 26.
Dupixent® (dupilumab) Approved in the U.S. as the First-ever …
WEB7 hours ago — Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Following recent approvals in the EU and China, the U.S. approval is based on two landmark Phase 3 trials that showed Dupixent achieved significant reduction in …
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB7 hours ago — They based their figure on 30% uptake of the treatment for those who are eligible. The addition would put Dupixent’s sales potential at $20 billion by the end of this decade, making it one of ...
Regeneron Announces Formation of Regeneron Cell Medicines …
WEBJan 30, 2024 — Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs. Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline.
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEB21 hours ago — European regulators approved Dupixent for COPD in July, but Regeneron and Sanofi have had to wait longer in the U.S., where the FDA requested additional efficacy data from the two trials. Over that time, a potential new competitor has emerged in GSK’s Nucala, which the FDA rejected in 2018 but earlier this month succeeded in a Phase 3 trial.
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEB7 hours ago — Sept. 27, 2024. West Coast Biotech & Life Sciences Reporter. Dupixent is already a blockbuster therapy for a range of immune-mediated diseases, but the Food and Drug Administration’s approval of ...
News Release - Regeneron Pharmaceuticals Inc.
WEBAug 20, 2024 — Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies.
Regeneron Announces New U.S. Government Agreement to …
WEBUnder the new agreement, Regeneron will supply an additional 1.4 million 1,200 mg doses of REGEN-COV to the U.S. government by January 31, 2022, at a cost of $2,100 per dose. This new agreement follows two earlier agreements with the U.S. government announced in July 2020 and January 2021.
Regeneron Announces Encouraging Topline Phase 2 Data of High …
WEBAug 24, 2021 — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that an ongoing Phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of EYLEA ® (aflibercept) Injection in patients with …
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
WEB21 hours ago — Regeneron REGN1.83%increase; green up pointing triangle Pharmaceuticals and Sanofi SAN 0.74%increase; green up pointing triangle have won U.S. Food and Drug Administration expanded approval of ...
Skip to content